Viewing StudyNCT05892653



Ignite Creation Date: 2024-05-06 @ 7:07 PM
Last Modification Date: 2024-10-26 @ 3:00 PM
Study NCT ID: NCT05892653
Status: RECRUITING
Last Update Posted: 2023-07-24
First Post: 2023-05-18

Brief Title: A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors
Sponsor:
Organization: ABM Therapeutics Shanghai Company Limited

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 52
Enrollment Type: ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE1
Observational Models:
Time Perspective List:
Who Masked List: